TD Asset Management
ABUS icon

TD Asset Management’s Arbutus Biopharma ABUS Stock Holding History

TD Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,200
Closed -$219K – 1385
2018
Q3 		$219K Buy
+23,200
New +$230K ﹤0.01% 1397

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TD Asset Management's ABUS Position: Q4 2018 in Review

TD Asset Management sold out of Arbutus Biopharma (ABUS) in Q4 2018, closing a stake of 23,200 shares — an estimated $219K sold.

TD Asset Management first reported a position in ABUS in Q3 2018 and held it in 1 quarter. The position peaked at $219K in Q3 2018. 71 funds tracked by Wall St. Rank hold ABUS as of Q4 2018.

  • TD Asset Management reported no remaining Arbutus Biopharma position as of Q4 2018 after selling out during the quarter.
  • TD Asset Management sold 23,200 Arbutus Biopharma shares in Q4 2018, an estimated $219K.
  • TD Asset Management first reported a position in Arbutus Biopharma in Q3 2018 and held it in 1 quarter.
  • TD Asset Management's Arbutus Biopharma position peaked at $219K in Q3 2018.
  • 71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2018.

Based on TD Asset Management's 13F filing for Q4 2018, filed 1 Feb 2019.